All In Biotech

Drug Trial Radar · NCT04944862

A Study of CDX-0159 in Patients With Prurigo Nodularis

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single Dose Study to Assess the Safety, Pharmacokinetics, and Clinical Effect of CDX-0159 in Patients With Prurigo Nodularis

Last checked: Nov 20, 2026Latest source record: Aug 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Nov 8, 2021

Primary completion

Jul 31, 2023

Study completion Jul 31, 2023

Sponsor

Lead sponsor
Celldex TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 30, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to explore the safety, clinical effect, pharmacodynamics, and pharmacokinetics of CDX-0159 (barzolvolimab) in patients with Prurigo Nodularis.

Conditions

  • Prurigo Nodularis

Interventions

  • CDX-0159Biological

    administered intravenously

  • Normal salineDrug

    administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability as assessed by the incidence and severity of adverse eventsTime frame: From Day 1 (first dose) to Day 169 (last follow-up visit)

Locations

17 sites in 3 countries. Site status is shown where the registry gives one.

  • Desert Sky Dermatology

    Tempe, Arizona

  • University of Miami, Dermatology Clinical Trials Unit

    Miami, Florida

  • Revival Research Institute, LLC

    Troy, Michigan

  • University of New Mexico

    Albuquerque, New Mexico

  • Markowitz Medical/Optiskin

    New York, New York

  • Central Sooner Research

    Norman, Oklahoma

  • Center for Clinical Studies, LTD.LLP

    Houston, Texas

  • Charité Centrum für Innere Medizin und Dermatologie, Institute of Allergology (IFA)

    Berlin, Germany

  • Katholisches Klinikum Bochum gGmbH, Dermatologische Studienambulanz

    Bochum, Germany

  • Universitatsklinikum Carl Gustav Carus Dresden, Klinik und Poliklinik fur Dermatologie

    Dresden, Germany

  • Universitätsklinikum Frankfurt Klinik für Dermatologie, Venerologie und Allergologie Klinische Forschung

    Frankfurt, Germany

  • Universitätsklinikum Erlangen Hautklinik

    Mainz, Germany

  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz Hautklinik, Clinical Research Center

    Mainz, Germany

  • Universitaetsklinikum Muenster (UKM) - Klinik für Hautkrankheiten

    Münster, Germany

  • MT Medic Specjalistyczna Praktyka Lekarska

    Krosno, Poland

  • IP Clinic Sp. z o.o.

    Lodz, Poland

  • Centrum Medyczne Ginemedica

    Wroclaw, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.